Rubin Marc

SEC source: 0001108205-26-000096 · wk-form4_1783627959.xml · derivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,800

Underlying: Common Stock · 6,800 shares

Expires 2036-07-06

F1 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 100% of the underlying shares on July 7, 2027.

SEC source: 0001108205-26-000036 · wk-form4_1774296147.xml · derivative · entry 2

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 26,667 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person.

F1 · price: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person.

F1 · derivative.exercise_date: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person.

F1 · derivative.expiration_date: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person.

SEC source: 0001108205-26-000036 · wk-form4_1774296147.xml · nonDerivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,108

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person.

SEC source: 0001108205-26-000024 · wk-form4_1773865248.xml · derivative · entry 4

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,667

Underlying: Common Stock · 26,667 shares

Expires 2027-07-08

F2 · price: Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person.

F5 · derivative.exercise_date: The Series C Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing on March 17, 2026.

SEC source: 0001108205-26-000024 · wk-form4_1773865248.xml · derivative · entry 3

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,667

Underlying: Common Stock · 26,667 shares

Expires not disclosed

F4 · derivative.exercise_price: The Series B Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series B Warrant) and will terminate upon the 30th calendar day following date on which the Company publicly announces that the fifth patient has been dosed in the Company's Phase 2 clinical trial of emavusertib in combination with an approved Bruton Tyrosine Kinase Inhibitor in chronic lymphocytic leukemia ("Initial Termination Date"). If the closing sale price of the Company's Common Stock at the Initial Termination Date is below $0.75 (the "Exercise Price"), such Exercise Price will be reset to the closing sale price of the Company's Common Stock on the Initial Termination Date (provided that the Exercise Price will not be reduced to less than 50% of the initial Exercise Price) and the Initial Termination Date will be extended an additional 30 days.

F2 · price: Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person.

F4 · derivative.exercise_date: The Series B Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series B Warrant) and will terminate upon the 30th calendar day following date on which the Company publicly announces that the fifth patient has been dosed in the Company's Phase 2 clinical trial of emavusertib in combination with an approved Bruton Tyrosine Kinase Inhibitor in chronic lymphocytic leukemia ("Initial Termination Date"). If the closing sale price of the Company's Common Stock at the Initial Termination Date is below $0.75 (the "Exercise Price"), such Exercise Price will be reset to the closing sale price of the Company's Common Stock on the Initial Termination Date (provided that the Exercise Price will not be reduced to less than 50% of the initial Exercise Price) and the Initial Termination Date will be extended an additional 30 days.

F4 · derivative.expiration_date: The Series B Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series B Warrant) and will terminate upon the 30th calendar day following date on which the Company publicly announces that the fifth patient has been dosed in the Company's Phase 2 clinical trial of emavusertib in combination with an approved Bruton Tyrosine Kinase Inhibitor in chronic lymphocytic leukemia ("Initial Termination Date"). If the closing sale price of the Company's Common Stock at the Initial Termination Date is below $0.75 (the "Exercise Price"), such Exercise Price will be reset to the closing sale price of the Company's Common Stock on the Initial Termination Date (provided that the Exercise Price will not be reduced to less than 50% of the initial Exercise Price) and the Initial Termination Date will be extended an additional 30 days.

SEC source: 0001108205-26-000024 · wk-form4_1773865248.xml · derivative · entry 2

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,667

Underlying: Common Stock · 26,667 shares

Expires 2031-01-08

F2 · price: Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person.

F3 · derivative.exercise_date: Each Series A Warrant became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series A Warrant) on March 17, 2026.

SEC source: 0001108205-26-000024 · wk-form4_1773865248.xml · derivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20

Underlying: Common Stock · 26,667 shares

Expires not disclosed

F1 · derivative.exercise_price: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converts into 1,333.33 shares of Common Stock for no additional consideration at 5 p.m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations).

F2 · price: Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person.

F1 · derivative.exercise_date: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converts into 1,333.33 shares of Common Stock for no additional consideration at 5 p.m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations).

F1 · derivative.expiration_date: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converts into 1,333.33 shares of Common Stock for no additional consideration at 5 p.m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations).

SEC source: 0001108205-25-000066 · wk-form4_1747944786.xml · derivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,400

Underlying: Common Stock · 14,400 shares

Expires 2035-01-27

F1 · date: This option grant, as disclosed in Curis Inc.'s 2025 proxy statement, was approved by the Board of Directors of Curis, Inc. on January 28, 2025, contingent upon shareholder approval of Curis's Amendment No. 1 to the Fifth Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if Amendment No. 1 to the Fifth Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 20, 2025, at the 2025 annual meeting of shareholders, Curis's shareholders approved Amendment No. 1 to the Fifth Amended and Restated 2010 Plan.

F2 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 100% of the underlying shares on January 28, 2026.

SEC source: 0001108205-25-000010 · wk-form4_1738271192.xml · derivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,600

Underlying: Common Stock · 1,600 shares

Expires 2035-01-27

F1 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 100% of the underlying shares on January 28, 2026.

SEC source: 0001133416-25-000018 · form4.xml · derivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2035-01-23

F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest 100% on December 31, 2025.

SEC source: 0001108205-24-000051 · wk-form4_1716494958.xml · derivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,250

Underlying: Common Stock · 4,250 shares

Expires 2034-01-19

F1 · date: This option grant, as disclosed in Curis Inc.'s 2024 proxy statement, was approved by the Board of Directors of Curis, Inc. on January 20, 2024, contingent upon shareholder approval of Curis's Fifth Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the Fifth Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 21, 2024, at the 2024 annual meeting of shareholders, Curis's shareholders approved the Fifth Amended and Restated 2010 Plan.

F2 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 100% of the underlying shares on January 20, 2025.

SEC source: 0001133416-24-000022 · form4.xml · derivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-01-24

F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest 100% on December 31, 2024.

SEC source: 0001133416-23-000026 · form4.xml · derivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2033-01-26

F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest 100% on December 31, 2023.

SEC source: 0001108205-23-000014 · wf-form4_167459484097220.xml · derivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2033-01-22

F1 · derivative.exercise_date: Options granted under the 2010 Amended and Restated Stock Incentive Plan and will vest as to 100% of the underlying shares on the first anniversary of the date of grant (January 23, 2024), subject to the director's continued service with the Company.

SEC source: 0001209191-22-005691 · doc4.xml · derivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common stock · 85,000 shares

Expires 2032-01-30

F1 · derivative.exercise_date: Options granted under the 2010 Amended and Restated Stock Incentive Plan and will vest as to 100% of the underlying shares on the first anniversary of the date of grant (January 31, 2023), subject to the director's continued service with the Company.

SEC source: 0001133416-22-000031 · form4.xml · derivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-01-24

F1 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest 100% on December 31, 2022.

SEC source: 0001104659-22-001616 · tm221868-1_4seq1.xml · derivative · entry 1

Rubin Marc · CIK 0001412377 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2032-01-05

F1 · derivative.exercise_date: The options vest as to 32,500 shares on July 5, 2022 with the balance to vest in equal monthly installments over the 18 months thereafter.

SEC source: 0000899243-21-013808 · doc4.xml · derivative · entry 2

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2031-03-25

F1 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan.

F3 · derivative.exercise_date: Such options vest when (i) the Company has received the interim results of its NAVIGATE clinical trial and (ii) makes a public announcement that it has received the interim results.

SEC source: 0000899243-21-013808 · doc4.xml · derivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2031-03-25

F1 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: Such options vest 100% on March 31, 2022.

SEC source: 0001104659-21-020181 · tm216217-5_4.xml · derivative · entry 1

Rubin Marc · CIK 0001412377 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2031-02-10

F1 · derivative.exercise_date: The options vest as to 75,000 shares on August 10, 2021 with the balance to vest in equal monthly installments over the 18 months thereafter.

SEC source: 0001209191-21-006100 · doc4.xml · derivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,000

Underlying: Common stock · 33,000 shares

Expires 2031-01-27

F1 · derivative.exercise_date: Options granted under the 2010 Amended and Restated Stock Incentive Plan and will vest as to 100% of the underlying shares on the first anniversary of the date of grant (January 28, 2022), subject to the director's continued service with the Company.

SEC source: 0001209191-20-016244 · doc4.xml · derivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common stock · 180,000 shares

Expires 2030-03-01

F1 · derivative.exercise_date: Options granted under the 2010 Amended and Restated Stock Incentive Plan and will vest as to 100% of the underlying shares on the first anniversary of the date of grant (March 2, 2021), subject to the director's continued service with the Company.

SEC source: 0000899243-20-001119 · doc4.xml · derivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2030-01-09

F1 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest 100% on December 31, 2020.

SEC source: 0001144204-19-018018 · tv517980_4.xml · derivative · entry 1

Rubin Marc · CIK 0001412377 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2029-04-02

F1 · derivative.exercise_date: The options vest as to 83,334 shares on the grant date with the balance to vest at such time, if ever, as the Company receives shareholder approval of the Board's amendment to Section 5.1 of the Company's option plan to increase the limitation on the number of awards granted to a single individual in any calendar year from 83,334 to 250,000.

SEC source: 0001179022-19-000027 · edgar.xml · derivative · entry 7

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,065

Underlying: Common Stock · 859 shares

Expires 2026-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 10, 2018.

F4 · derivative.exercise_date: The options vested 100% on December 14, 2018.

SEC source: 0001179022-19-000027 · edgar.xml · nonDerivative · entry 5

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,581

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 10, 2018.

F3 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.02. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001179022-19-000027 · edgar.xml · nonDerivative · entry 4

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,440

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 10, 2018.

SEC source: 0001179022-19-000027 · edgar.xml · derivative · entry 6

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,924

Underlying: Common Stock · 43,326 shares

Expires 2026-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 10, 2018.

F4 · derivative.exercise_date: The options vested 100% on December 14, 2018.

SEC source: 0001179022-19-000027 · edgar.xml · nonDerivative · entry 3

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,581

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 10, 2018.

F2 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.05. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001179022-19-000027 · edgar.xml · nonDerivative · entry 2

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,907

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 10, 2018.

SEC source: 0001179022-19-000027 · edgar.xml · nonDerivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,581

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 10, 2018.

SEC source: 0001209191-19-005352 · doc4.xml · nonDerivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,819

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan to cover tax obligations.

F2 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.09, inclusive. The reporting person undertakes to provide to Curis, Inc., any security holder of Curis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth on this Form 4.

F3 · balance_after: On May 29, 2018, the Company effected a 1-for-5 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

SEC source: 0001209191-19-004993 · doc4.xml · derivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2029-01-20

F1 · derivative.exercise_date: Options granted under the 2010 Amended and Restated Stock Incentive Plan and will vest in twelve equal monthly installments beginning on February 21, 2019 until the award becomes fully vested on January 21, 2020, subject to the director's continued service with the Company.

SEC source: 0001179022-19-000011 · edgar.xml · derivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common stock · 25,000 shares

Expires 2029-01-16

F1 · derivative.exercise_date: The options vest 100% on January 16, 2020.

SEC source: 0001144204-18-050779 · tv503425_4.xml · derivative · entry 2

Rubin Marc · CIK 0001412377 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,000

Underlying: common stock · 400,000 shares

Expires 2023-09-25

SEC source: 0001144204-18-050779 · tv503425_4.xml · nonDerivative · entry 1

Rubin Marc · CIK 0001412377 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 556,317

SEC source: 0001179022-18-000070 · edgar.xml · derivative · entry 3

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,500

Underlying: Common Stock · 6,000 shares

Expires 2026-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 10, 2018.

F2 · derivative.exercise_date: The options vested 100% on December 14, 2017, the date of Galectin Therapeutics, Inc.'s 2017 Annual Stockholders Meeting.

SEC source: 0001179022-18-000070 · edgar.xml · nonDerivative · entry 2

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,581

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 10, 2018.

F3 · price: The shares were sold in multiple transactions at prices ranging from $6.50 to $6.67. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001179022-18-000070 · edgar.xml · nonDerivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,481

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 10, 2018.

SEC source: 0001179022-18-000069 · edgar.xml · derivative · entry 3

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 29,000 shares

Expires 2026-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 10, 2018.

F2 · derivative.exercise_date: The options vested 100% on December 14, 2017, the date of Galectin Therapeutics, Inc.'s 2017 Annual Stockholders Meeting.

SEC source: 0001179022-18-000069 · edgar.xml · nonDerivative · entry 2

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,481

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 10, 2018.

F3 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.53. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001179022-18-000069 · edgar.xml · nonDerivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,581

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 10, 2018.

SEC source: 0001144204-18-013884 · tv488099_form4.xml · derivative · entry 1

Rubin Marc · CIK 0001412377 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,000

Underlying: Common Stock · 170,000 shares

Expires 2028-03-07

F1 · derivative.exercise_date: The options vest as to 25% on the grant date and 25% on each of the three month, six month and nine month anniversaries of the grant date.

SEC source: 0001209191-18-005150 · doc4.xml · nonDerivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 236,596

F1 · shares: This award is in the form of restricted common stock. The award vests as to 100% of the underlying shares on the first anniversary of the date of grant.

F2 · balance_after: Represents 51,596 shares of unrestricted common stock and 185,000 shares of restricted common stock.

SEC source: 0001179022-17-000082 · edgar.xml · derivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,250

Underlying: Common stock · 77,250 shares

Expires 2027-12-14

F1 · derivative.exercise_date: The options vest 100% on December 14, 2018.

SEC source: 0001179022-17-000071 · edgar.xml · nonDerivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,581

F1 · price: The footnote on the original Form 4, filed on December 8, 2017, incorrectly indicated that the shares were sold, instead of purchased, in multiple transactions. The shares were purchased in multiple transactions at prices ranging from $1.819 to $1.92. This amount represents the weighted average purchase price of such transactions. The reporting person undertakes to provide full information regarding the number of shares purchased at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001179022-17-000069 · edgar.xml · nonDerivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,581

F1 · price: The shares were sold in multiple transactions at prices ranging from $1.819 to $1.92. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001209191-17-061106 · doc4.xml · nonDerivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,596

F1 · price: These shares were purchased between $0.975-$0.984/share. The Company will provide, upon request, full information regarding the number of shares purchased at each separate price.

SEC source: 0001209191-17-016730 · doc4.xml · derivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2027-02-27

F1 · derivative.exercise_date: Options granted under the 2010 Amended and Restated Stock Incentive Plan and 1/12th of the total shares will vest monthly beginning on January 1, 2017 until all of the shares underlying the award become vested on January 1, 2018, subject to the director's continued service with the Company.

SEC source: 0001144204-17-008582 · v459418_form4.xml · derivative · entry 1

Rubin Marc · CIK 0001412377 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2027-02-13

F1 · derivative.exercise_date: The options vest in 24 equal monthly installments commencing on the grant date.